AR104792A1 - AGENTS THAT LINK TO TIGIT AND USES OF THE SAME - Google Patents

AGENTS THAT LINK TO TIGIT AND USES OF THE SAME

Info

Publication number
AR104792A1
AR104792A1 ARP160101537A ARP160101537A AR104792A1 AR 104792 A1 AR104792 A1 AR 104792A1 AR P160101537 A ARP160101537 A AR P160101537A AR P160101537 A ARP160101537 A AR P160101537A AR 104792 A1 AR104792 A1 AR 104792A1
Authority
AR
Argentina
Prior art keywords
seq
agents
tigit
heavy chain
light chain
Prior art date
Application number
ARP160101537A
Other languages
Spanish (es)
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of AR104792A1 publication Critical patent/AR104792A1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan agentes que específicamente se enlazan a TIGIT (Inmunorreceptor de células T con los dominios Ig e ITIM). Los agentes que se enlazan a TIGIT pueden incluir polipéptidos, anticuerpos, y/o agentes biespecíficos. Asimismo se divulgan métodos de uso de los agentes para estimular la respuesta inmune y/o el tratamiento de las enfermedades tal como el cáncer. Reivindicación 1: Un anticuerpo aislado que específicamente se enlaza al dominio extracelular de TIGIT humano, que comprende: (a) una CDR1 de cadena pesada que comprende TSDYAWN (SEC ID Nº 57), una CDR2 de cadena pesada que comprende YISYSGSTSYNPSLRS (SEC ID Nº 58), y una CDR3 de cadena pesada que comprende ARRQVGLGFAY (SEC ID Nº 59), y (b) una CDR1 de cadena ligera que comprende KASQDVSTAVA (SEC ID Nº 60), una CDR2 de cadena ligera que comprende SASYRYT (SEC ID Nº 61), y una CDR3 de cadena ligera que comprende QQHYSTP (SEC ID Nº 62).Agents that specifically bind to TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are disclosed. Agents that bind to TIGIT may include polypeptides, antibodies, and / or bispecific agents. Methods of using agents to stimulate the immune response and / or the treatment of diseases such as cancer are also disclosed. Claim 1: An isolated antibody that specifically binds to the extracellular domain of human TIGIT, comprising: (a) a heavy chain CDR1 comprising TSDYAWN (SEQ ID No. 57), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID No. 58), and a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID No. 59), and (b) a light chain CDR1 comprising KASQDVSTAVA (SEQ ID No. 60), a light chain CDR2 comprising SASYRYT (SEQ ID NO. 61), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO. 62).

ARP160101537A 2015-05-28 2016-05-27 AGENTS THAT LINK TO TIGIT AND USES OF THE SAME AR104792A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562167582P 2015-05-28 2015-05-28

Publications (1)

Publication Number Publication Date
AR104792A1 true AR104792A1 (en) 2017-08-16

Family

ID=59714861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101537A AR104792A1 (en) 2015-05-28 2016-05-27 AGENTS THAT LINK TO TIGIT AND USES OF THE SAME

Country Status (1)

Country Link
AR (1) AR104792A1 (en)

Similar Documents

Publication Publication Date Title
CL2018003583A1 (en) Anti-pd-l1 antibodies and uses thereof.
CY1124771T1 (en) ANTI-SORTILINE ANTIBODIES AND METHODS OF USING THEM
CL2020000263A1 (en) Monoclonal antibody against bcma-drug conjugate.
MX2024001803A (en) ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM.
PY1829572A (en) HUMANIZED ANTIGEN-BINDING DOMAINS AND METHODS OF USE
CL2020002223A1 (en) Anti-pd-l1 antibodies and their uses
MX2021007768A (en) ANTI-CTLA4 ANTIBODIES AND METHODS OF USE THEREOF.
PE20210652A1 (en) HER2 TARGETING ANTIGEN BINDING MOLECULES INCLUDING 4-1BBL
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
CL2017003261A1 (en) Factor xi antibodies and methods of use
PE20160690A1 (en) HUMANIZED ANTI-CD134 (OX40) ANTIBODIES AND USES OF THEM
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
PE20240111A1 (en) BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
CL2017001660A1 (en) Antibodies against the T-cell immunoreceptor with immunoglobulin domains and tyrosine-based immunoreceptor inhibitory motif (tigit)
PE20191208A1 (en) ANTI-CD73 ANTIBODIES AND USES OF THEM
CL2018000744A1 (en) Anti-tigit antibodies (T lymphocyte immunoreceptor with ig and itim domains) and methods of use.
PE20190970A1 (en) ANTI-CD40 ANTIBODIES AND THEIR USES
CO2018002265A2 (en) Humanized anti-human cd19 antibodies
AR098465A1 (en) ANTI-a-SINUCLEINE ANTIBODIES AND METHODS OF USE
PE20180927A1 (en) LAG-3 BINDING MOLECULES AND METHODS OF USE OF THEM
MX2016012094A (en) COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT.
MX2017002230A (en) ANTI-LAG3 ANTIBODIES AND FRAGMENTS FROM UNION TO ANTIGEN.
MX373245B (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES.
AR101829A1 (en) CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER
PE20170125A1 (en) ANTIGENIC CHEMERIC RECEPTOR (CAR) THAT INCLUDES A DOMAIN OF UNION OF ANTIGENS, WHICH IS SELECTIVELY JOINED TO THE CONSTANT REGION OF THE TCR BETA 1 (TRBC1) OR TRBC2 OF T CELLS